Latest News

Wondering if Bureau Veritas at around €25.70 is offering good value today, or if the market is pricing it fairly. The share price closed at €25.70, with returns of 1.2% decline over the last week, 12.6% decline over the last month, and 4.2% decline year to date, while the 1 year return sits at 4.8% decline and longer term 3 year and 5 year returns are 6.6% and 19.1% respectively. These moves are drawing attention back to the core question of what the business is worth and how current...

Capital raise potential and what it could mean for XPLR Infrastructure (XIFR) XPLR Infrastructure (XIFR) has filed a US$300 million shelf registration for its common units, giving the partnership flexibility to issue equity as funding needs or investment plans emerge. See our latest analysis for XPLR Infrastructure. The shelf filing comes as XIFR’s share price sits at US$10.62, with a 1 day share price return of 4.94% and a 1 year total shareholder return of 13.83%. The 3 year total...

If you are asking whether EQT is attractively priced right now, the key is to look at what the current share price actually implies about the business. The stock recently closed at SEK 286.5, with returns of 4.6% over 7 days, 2.3% over 30 days, a 20.0% decline year to date, a 7.6% decline over 1 year, and a 42.1% gain over 3 years alongside a 4.9% gain over 5 years. Taken together, this gives a mixed picture of sentiment and risk. Recent coverage around EQT has focused on its role in the...

Alnylam Pharmaceuticals has reported new clinical and real world data on its RNAi therapy vutrisiran in ATTR-CM, highlighting durable benefits in quality of life and reductions in advanced disease progression and mortality. The company has also shared pooled Phase 2 safety data for zilebesiran that supports its move into a global Phase 3 trial in hypertension and cardiovascular risk reduction. For investors tracking NasdaqGS:ALNY, this update centers on the company’s core RNAi franchise and...

The Middle Eastern stock markets have recently experienced mixed performances, influenced by geopolitical developments such as the potential de-escalation of tensions involving Iran. For investors seeking opportunities in smaller or newer companies, penny stocks—despite their somewhat outdated name—remain a relevant and intriguing investment area. These stocks can offer significant growth potential at lower price points, especially when backed by strong financial foundations and solid...

The Middle East stock markets have recently experienced mixed performances, with Gulf stocks reacting to geopolitical developments such as the potential de-escalation of tensions involving Iran, impacting key indices and investor sentiment. Amidst this backdrop, identifying promising small-cap stocks requires a keen understanding of local economic fundamentals and market resilience, as these factors can offer unique opportunities for growth in an otherwise volatile environment.

UP Fintech Holding Limited recently reported its fourth-quarter and full-year 2025 results, with Q4 revenue of US$175.57 million and net income of US$45.23 million, and full-year revenue of US$612.06 million and net income of US$170.9 million, all higher than the prior year. The sharp rise in basic earnings per share from continuing operations to US$0.96 for 2025, up from US$0.375 a year earlier, highlights a significant improvement in profitability. We will now examine how this strong...

Wondering if National Health Investors is priced fairly today or if the current share price leaves some room on the table? This overview walks through what the recent numbers may be saying about value. The stock closed at US$80.86, with returns of 5.2% year to date and 14.2% over the last year, while the past 7 and 30 days have seen declines of 2.1% and 3.8% respectively. Recent coverage has focused on how real estate investment trusts are responding to changing conditions in healthcare...

Dah Sing Banking Group (SEHK:2356) opened FY 2025 with first half revenue of HK$3.1b and basic EPS of HK$1.12, setting the tone for a results season where profitability metrics are firmly in focus. Over the past three reported halves, total revenue has moved from HK$2.7b in 1H 2024 to HK$2.4b in 2H 2024 and then to HK$3.1b in 1H 2025, while basic EPS over the same periods went from HK$0.99 to HK$0.47 and then to HK$1.12, giving investors a clear read on how the income line is tracking through...

The stock was sluggish on the back of Elementis plc's ( LON:ELM ) recent earnings report. Our analysis suggests that...

Rentokil Initial plc's ( LON:RTO ) stock was strong despite it releasing a soft earnings report last week. We think...

Reckitt Benckiser Group plc's ( LON:RKT ) stock didn't jump after it announced some healthy earnings. Our analysis...

Market forces rained on the parade of Prodways Group SA ( EPA:ALPWG ) shareholders today, when the analysts downgraded...

Luceco plc's ( LON:LUCE ) strong earnings report was rewarded with a positive stock price move. Our analysis found some...

Vermilion Energy (TSX:VET) has drawn attention after strong recent share price moves, with returns of 31% over the past month and 68% over the past 3 months, prompting closer scrutiny of its fundamentals. See our latest analysis for Vermilion Energy. At the current share price of CA$19.17, Vermilion’s recent 30.85% 1 month share price return and 67.86% 3 month share price return point to strong momentum, while the 74.21% 1 year total shareholder return shows that recent gains build on a...

Despite posting some strong earnings, the market for Fincantieri S.p.A.'s ( BIT:FCT ) stock hasn't moved much. We did...

Sangamo Therapeutics (SGMO) closed out FY 2025 with Q4 revenue of US$14.2 million and a basic EPS loss of US$0.11, as net income excluding extra items came in at a loss of US$37.4 million. On a trailing twelve month basis, revenue was US$39.6 million with a basic EPS loss of US$0.44 and a net loss of US$122.9 million. The company has seen quarterly revenue range from US$0.6 million to US$49.4 million across the last six reported periods, with basic EPS moving between a loss of US$0.14 and a...

The most recent earnings report from Amplifon S.p.A. ( BIT:AMP ) was disappointing for shareholders. Despite the soft...

Atalaya Mining Copper, S.A. ( LON:ATYM ) shareholders will have a reason to smile today, with the analysts making...

The United Kingdom's stock market has faced recent challenges, with the FTSE 100 index experiencing a decline amid weak trade data from China, highlighting global economic interdependencies. In such uncertain times, identifying undervalued stocks can provide opportunities for investors seeking value in companies that may be trading below their intrinsic worth.

As the UK market faces challenges tied to global economic uncertainties, particularly with China's faltering trade data impacting the FTSE indices, investors are increasingly focused on identifying resilient growth companies. In such an environment, firms with high insider ownership often capture attention due to their potential alignment of interests between management and shareholders, suggesting a vested interest in long-term success.

The London stock market has recently faced downward pressure, with the FTSE 100 and FTSE 250 indices slipping due to weak trade data from China, highlighting ongoing global economic challenges. Despite these broader market conditions, penny stocks—often representing smaller or newer companies—continue to attract interest for their growth potential at more accessible price points. While the term "penny stocks" might seem outdated, they remain relevant as investors seek out opportunities in...

As the FTSE 100 and FTSE 250 indices experience downward pressure due to weak trade data from China, investors in the UK are navigating a challenging market environment. In such conditions, dividend stocks can offer a degree of stability and income potential, making them an attractive option for those seeking to bolster their portfolios amid global economic uncertainties.

The recent 16% drop in Headlam Group plc's ( LON:HEAD ) stock could come as a blow to insiders who purchased UK£58.2k...